Equities

Xenetic Biosciences Inc

Xenetic Biosciences Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)3.97
  • Today's Change0.22 / 5.87%
  • Shares traded5.51k
  • 1 Year change-30.29%
  • Beta2.2571
Data delayed at least 15 minutes, as of Sep 20 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 19-Sep-24
Select bar for recommendation details.
Recommendations19-Sep-24
Buy0
Outperform0
Hold1
Sell0
Strong Sell0

Share price forecast in USD

The one analyst offering a 12 month price target expects Xenetic Biosciences Inc share price to rise to 40.00 in the next year from the last price of 3.97.
High907.6%40.00
Med907.6%40.00
Low907.6%40.00

Earnings history & estimates in USD

On Aug 13, 2024, Xenetic Biosciences Inc reported 2nd quarter 2024 losses of -0.83 per share. This result was in line with the expectation of the one analyst following the company and under-performed last year's 2nd quarter results by 20.29%.
The next earnings announcement is expected on Nov 07, 2024.
Average growth rate-4.83%
Xenetic Biosciences Inc reported annual 2023 losses of -2.71 per share on Mar 21, 2024.
Average growth rate+52.26%
More ▼

Revenue history & estimates in USD

Xenetic Biosciences, Inc. had 2nd quarter 2024 revenues of 726.00k. This bettered the 540.00k estimate of the one analyst covering the company. This was 19.80% above the prior year's 2nd quarter results.
Average growth rate+5.49%
Xenetic Biosciences, Inc. had revenues for the full year 2023 of 2.54m. This was 48.89% above the prior year's results.
Average growth rate+683.02%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.